Close Menu

Isis

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

Interleukin will provide its genetic tests for inflammatory and metabolic diseases for a study directed at a cardiovascular disease drug in development.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) — A recent case study has shown the utility of combined PCR/electrospray ionization mass spectrometry (PCR/ESI-MS) for detecting a rare pathogen in a case of meningitis.

NEW YORK (GenomeWeb) – Researchers from Isis Pharmaceuticals this week published new data demonstrating the ability of a novel GalNAc conjugate to boost the potency of antisense oligonucleotides (ASOs) — including two it currently has in human trials — by as much as 10 fold in mice.

NEW YORK (GenomeWeb News) – KineMed said this week that it has extended its collaboration with the CHDI Foundation on research into biomarkers for Huntington's disease.

A US District Court last week denied Santaris Pharma's second bid to have a patent-infringement lawsuit filed against it by Isis Pharmaceuticals thrown out, ruling that the company again failed to establish that its allegedly infringing activities were protected by a US statute t

Isis Pharmaceuticals this month took issue with Santaris Pharma's latest attempt to use a safe harbor provision in US law to fend off patent infringement charges in the companies' ongoing legal war, arguing in a court filing that the legal protection only covers the development o

Santaris Pharma last week made another push to end the legal attack against it by Isis Pharmaceuticals, asking for the court that is hearing the companies' intellectual property lawsuit to rule that there was no infringement of the patents at the heart of the case.

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

Pages

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.